Most
of the people who are suffering from end-stage renal disease undergo
hemodialysis, and is often accompanied by recurrent and troubling
side-effects, which are referred to as intra-dialytic hypotension
(IDH). IDH has been estimated to affect around 15% to 55% of all
patients undergoing hemodialysis. Some of the major symptoms of IDH
include nausea, diaphoresis and cramps, to more precarious conditions
that include angina pectoris, arrhythmias, seizures, unconsciousness
and even cardiac arrests. IDH is mainly caused due to inefficient
cardiovascular response to the reduced blood volume, which is bound
to occur due to the removal of large volumes of water in a very short
span. As a typical hemodialysis procedure involves the removal of an
ultrafiltrate volume of water from the patient’s body, which is
equal to or even greater than the entire blood plasma of the patient.
The
occurrence of IDH would increase further due to ageing population
that exhibit greater comorbidities, such as cardiovascular problems
and diabetes, thus making IDH a problem that requires extensive
rethinking and innovation. Several drug developers and manufacturers
are involved in extensive research and development and many of them
have a considerable number of drugs in different stages of clinical
trials in this field. Some of the important drugs that are in
different stages of clinical trials that will soon be commercialized
in the global market include, MTR107, Droxidopa, Mannitol, Northera
and Norathiol among others.
Some
of the major driving factors for the growth of this market include,
high number of patients undergoing hemodialysis, aging population,
rising demand for advanced therapeutics, high number of drugs in the
pipeline and rising awareness and affordability of the people
globally. At present, many people are undergoing hemodialysis due to
kidney failure or end stage renal diseases, which in turn increase
the chances of developing IDH, thus, will contribute towards the
growth of this market in future. Also, aged individuals increasingly
require hemodialysis, hence are more prone towards IDH, hence will
add to this market’s growth in future. Comorbidities such as,
diabetes and cardiovascular diseases also increase the chances of
developing renal disorders, hence in turn will increase IDH
occurrences, hence the demand for advanced therapeutics. Thus, rising
awareness and demand along with high number of pipeline drugs that
will soon be commercialized in the global market will augment the
growth of this market in the near future.
Geographically,
North America and Europe are expected to dominate the global
intra-dialytic hypotension market. Some of the key factors that are
expected to be responsible for their dominance in this market are
high number of patients undergoing renal hemodialysis along with the
presence of large geriatric population in these regions. Most of the
companies that are involved in the research and development
activities in this field and have a few drugs in the pipeline also
belong to these regions. Thus, it is expected that these regions will
largely dominate this market in future. However, Asia Pacific that
constitutes some of the fastest emerging economies of the world along
with increasing number of patients with renal diseases will help grow
this market in this region in future.
Some
of the major players having their drugs in different stages of
clinical trials in this market include, Advanced Circulatory Systems,
Inc., B. Braun Melsungen AG, Chelsea Therapeutics, Inc., Global
Monitors, Inc., Medinox, Inc., Meditor Pharmaceuticals Ltd. and
Wolfson Medical Center.
Enquiry
Before Buying :-
Browse
Market Research Blog:
